Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab + chidamide + etoposide/gemcitabine for relapsed/refractory peripheral T-cell lymphoma
ChiCTR2300068673Phase 4Recruiting
- Sponsor
- Beijing Chaoyang Sanhuan Cancer Hospital
- Start
- Oct 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zimberelimab, tucidinostat, etoposide and gemcitabine in peripheral T-cell lymphoma (PTCL), sponsored by Beijing Chaoyang Sanhuan Cancer Hospital. Primary endpoint: Overall response rate (ORR). Started Oct 2022; status: recruiting.
02
Drugs
zimberelimabtucidinostatetoposidegemcitabine
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2300068673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068673.